Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thioredoxin-interacting protein (TXNIP) is a member of the α-arrestin family that acts as an endogenous inhibitor of thioredoxin (TRX). By binding to TRX, TXNIP modulates cellular redox reactions, glucose homeostasis, inflammation, and cell death. It plays a complex role in various diseases, acting as a tumor suppressor in some cancers while contributing to the pathogenesis of metabolic syndromes and neurodegenerative disorders. Its role in regulating oxidative stress makes it a potential therapeutic target, but also presents safety concerns due to its complex interactions and downstream effects.
Inhibition of thioredoxin (TRX) via disulfide bond formation, leading to increased intracellular ROS levels and oxidative stress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thioredoxin-Interacting Protein (TXNIP).